Cefalonium API Manufacturers & Suppliers

Cefalonium, with CAS number 5575-21-3, is an experimental veterinary cephalosporin antibiotic. It belongs to the class of beta-lactam antibiotics characterized by a fused bicyclic ring system consisting of a 1,2-thiazine and a 2-azetidinone moiety. These structural features underpin its antibacterial activity typical of cephalosporins.

Cefalonium is primarily used in veterinary medicine, approved for use in certain animal treatments. Its clinical indications generally align with those of other cephalosporins, targeting bacterial infections caused by susceptible gram-positive and gram-negative organisms. Specific approved indications, dosing regimens, and species applications depend on regional regulatory approvals and veterinary clinical guidelines.

Pharmacologically, cefalonium disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the cross-linking of peptidoglycan layers critical for cell wall integrity. This mechanism leads to bacterial cell lysis and death, characteristic of beta-lactam antibiotics.

Pharmacokinetic data, including absorption, distribution, metabolism, and excretion parameters, are limited for cefalonium. Generally, cephalosporins demonstrate variable oral bioavailability, with parenteral administration more common in veterinary settings. Elimination typically occurs via renal excretion, but specific ADME profiles for cefalonium require further elucidation.

Safety considerations for cefalonium involve potential hypersensitivity reactions common to beta-lactams, including anaphylaxis and allergic skin reactions. As with other cephalosporins, caution is advised in animals with known beta-lactam allergies. Toxicity data are primarily derived from veterinary studies, and human safety profiles are not established.

Cefalonium is marketed under various trade names within veterinary pharmaceutical portfolios. Its use is confined to animal health, with no approvals for human medical application.

For formulation scientists and procurement specialists, sourcing quality-assured cefalonium API requires compliance with veterinary pharmaceutical standards and verification of batch consistency. Given its experimental and veterinary-approved status, manufacturers should ensure adherence to Good Manufacturing Practices (GMP) and regulatory requirements pertinent to animal health products. Certificates of analysis and impurity profiles must be thoroughly reviewed during API procurement to maintain product safety and efficacy.